Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.
Evogene (NYSE:EVGN) Receives News Impact Score of 0.22
Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.
Evogene (NYSE EVGN) opened at 4.80 on Monday. The company’s market capitalization is $123.58 million. Evogene has a 12 month low of $4.57 and a 12 month high of $7.09. The stock’s 50 day moving average is $5.03 and its 200-day moving average is $5.15.
Evogene (NYSE:EVGN) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.05. Evogene had a negative net margin of 235.47% and a negative return on equity of 18.60%. The business had revenue of $1.18 million during the quarter. On average, analysts expect that Evogene will post ($0.71) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “[[title]]” was published by [[site]] and is owned by of [[site]]. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at [[permalink]].
Evogene Company Profile
Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.